$OPRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in OptimizeRx Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in OptimizeRx Corp. Get notifications about new insider transactions in OptimizeRx Corp for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 11 2018 | OPRX | OptimizeRx Corp | WPP plc | 10% Owner | Buy | J | 1.50 | 300,000 | 450,000 | 6,311,106 | 6 M to 6.3 M (+4.99 %) |
Feb 02 2018 | OPRX | OptimizeRx Corp | BAKER DOUGLAS P | Chief Financial Off ... | Option Exercise | A | 0.00 | 50,000 | 0 | 550,000 | |
Feb 02 2018 | OPRX | OptimizeRx Corp | FEBBO WILLIAM J | Chief Executive Off ... | Option Exercise | A | 0.00 | 240,000 | 0 | 1,740,000 | |
Feb 02 2018 | OPRX | OptimizeRx Corp | Hamilton Terrence | SVP of Sales | Option Exercise | A | 0.00 | 50,000 | 0 | 450,000 | |
Feb 02 2018 | OPRX | OptimizeRx Corp | Paramore Miriam J | President | Option Exercise | A | 0.00 | 50,000 | 0 | 550,000 | |
Jan 12 2018 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 116,269 | 110 K to 116.3 K (+5.68 %) |
Jan 12 2018 | OPRX | OptimizeRx Corp | Lang James Paul | Director | Grant | A | 0.00 | 6,250 | 0 | 25,000 | 18.8 K to 25 K (+33.33 %) |
Jan 12 2018 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.00 | 6,250 | 0 | 812,329 | 806.1 K to 812.3 K (+0.78 %) |
Oct 06 2017 | OPRX | OptimizeRx Corp | Paramore Miriam J | PRESIDENT | Buy | P | 1.21 | 8,690 | 10,529 | 8,690 | 0 to 8.7 K |
Oct 02 2017 | OPRX | OptimizeRx Corp | Lang James Paul | Director | Grant | A | 0.00 | 6,250 | 0 | 18,750 | 12.5 K to 18.8 K (+50.00 %) |
Oct 02 2017 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 110,019 | 103.8 K to 110 K (+6.02 %) |
Oct 02 2017 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.00 | 6,250 | 0 | 806,079 | 799.8 K to 806.1 K (+0.78 %) |
Jun 30 2017 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.00 | 6,250 | 0 | 799,829 | 793.6 K to 799.8 K (+0.79 %) |
Jun 30 2017 | OPRX | OptimizeRx Corp | Lang James Paul | Director | Grant | A | 0.00 | 6,250 | 0 | 12,500 | 6.3 K to 12.5 K (+100.00 %) |
Jun 30 2017 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 103,769 | 97.5 K to 103.8 K (+6.41 %) |
Jun 02 2017 | OPRX | OptimizeRx Corp | Harrell David | Director | Sell | D | 0.78 | 500,000 | 390,000 | 2,090,750 | 2.6 M to 2.1 M (-19.30 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 1,000 | 750 | 28,000 | 27 K to 28 K (+3.70 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.74 | 2,000 | 1,480 | 27,000 | 25 K to 27 K (+8.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 25,000 | 24 K to 25 K (+4.17 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 24,000 | 23 K to 24 K (+4.35 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 2,000 | 1,620 | 23,000 | 21 K to 23 K (+9.52 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.80 | 1,000 | 800 | 21,000 | 20 K to 21 K (+5.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 20,000 | 19 K to 20 K (+5.26 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 19,000 | 18 K to 19 K (+5.56 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.82 | 2,000 | 1,640 | 18,000 | 16 K to 18 K (+12.50 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.85 | 1,000 | 850 | 16,000 | 15 K to 16 K (+6.67 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 2,000 | 1,620 | 15,000 | 13 K to 15 K (+15.38 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 13,000 | 12 K to 13 K (+8.33 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.85 | 1,000 | 850 | 12,000 | 11 K to 12 K (+9.09 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.70 | 1,000 | 700 | 11,000 | 10 K to 11 K (+10.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.71 | 1,000 | 710 | 10,000 | 9 K to 10 K (+11.11 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 1,000 | 750 | 9,000 | 8 K to 9 K (+12.50 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.77 | 1,000 | 770 | 8,000 | 7 K to 8 K (+14.29 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.70 | 2,000 | 1,400 | 7,000 | 5 K to 7 K (+40.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 2,000 | 1,500 | 5,000 | 3 K to 5 K (+66.67 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.73 | 1,000 | 730 | 3,000 | 2 K to 3 K (+50.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.76 | 1,000 | 760 | 2,000 | 1,000 to 2 K (+100.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.77 | 1,000 | 770 | 1,000 | 0 to 1,000 |
May 15 2017 | OPRX | OptimizeRx Corp | BAKER DOUGLAS P | CHIEF FINANCIAL OFF ... | Buy | P | 0.77 | 10,000 | 7,700 | 50,000 | 40 K to 50 K (+25.00 %) |
Apr 06 2017 | OPRX | OptimizeRx Corp | Lang James Paul | Director | Grant | A | 0.00 | 6,250 | 0 | 6,250 | 0 to 6.3 K |
Apr 04 2017 | OPRX | OptimizeRx Corp | Hamilton Terrence | SVP OF SALES | Option Exercise | A | 0.82 | 200,000 | 164,000 | 200,000 | |
Apr 04 2017 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 97,519 | 91.3 K to 97.5 K (+6.85 %) |
Mar 21 2017 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Buy | P | 0.77 | 16,990 | 13,082 | 91,269 | 74.3 K to 91.3 K (+22.87 %) |
Mar 21 2017 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Buy | P | 0.77 | 5,000 | 3,850 | 74,279 | 69.3 K to 74.3 K (+7.22 %) |
Mar 15 2017 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Buy | P | 0.74 | 8,010 | 5,927 | 69,279 | 61.3 K to 69.3 K (+13.07 %) |
Jan 04 2017 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.00 | 6,250 | 0 | 787,329 | 781.1 K to 787.3 K (+0.80 %) |
Jan 04 2017 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 61,269 | 55 K to 61.3 K (+11.36 %) |
Dec 21 2016 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Buy | P | 0.80 | 4,000 | 3,200 | 781,079 | 777.1 K to 781.1 K (+0.51 %) |
Dec 05 2016 | OPRX | OptimizeRx Corp | FEBBO WILLIAM J | Chief Executive Off ... | Buy | P | 0.85 | 4,000 | 3,400 | 44,000 | 40 K to 44 K (+10.00 %) |
Nov 15 2016 | OPRX | OptimizeRx Corp | Hamilton Terrence | SENIOR VP OF SALES | Buy | P | 0.90 | 7,000 | 6,300 | 387,413 | 380.4 K to 387.4 K (+1.84 %) |
Nov 14 2016 | OPRX | OptimizeRx Corp | BAKER DOUGLAS P | CHIEF FINANCIAL OFF ... | Buy | P | 0.85 | 10,000 | 8,500 | 40,000 | 30 K to 40 K (+33.33 %) |
Nov 14 2016 | OPRX | OptimizeRx Corp | FEBBO WILLIAM J | CHIEF EXECUTIVE OFF ... | Buy | P | 0.90 | 9,000 | 8,100 | 40,000 | 31 K to 40 K (+29.03 %) |
Jul 29 2016 | OPRX | OptimizeRx Corp | Hamilton Terrence | SVP OF SALES | Option Exercise | A | 1.15 | 200,000 | 230,000 | 200,000 | |
Jul 29 2016 | OPRX | OptimizeRx Corp | Dillon Brian J | SR. VP OF PRODUCT & ... | Option Exercise | A | 1.15 | 100,000 | 115,000 | 100,000 | |
Jul 15 2016 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.00 | 6,250 | 0 | 777,079 | 770.8 K to 777.1 K (+0.81 %) |
Jul 15 2016 | OPRX | OptimizeRx Corp | Hamilton Terrence | VP OF SALES | Option Exercise | J | 0.00 | 384,188 | 0 | 0 | |
Jul 15 2016 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 55,019 | 48.8 K to 55 K (+12.82 %) |
Jun 10 2016 | OPRX | OptimizeRx Corp | FEBBO WILLIAM J | CHIEF EXECUTIVE OFF ... | Buy | P | 1.10 | 11,567 | 12,724 | 31,000 | 19.4 K to 31 K (+59.52 %) |
Jun 10 2016 | OPRX | OptimizeRx Corp | FEBBO WILLIAM J | CHIEF EXECUTIVE OFF ... | Buy | P | 1.06 | 10,000 | 10,600 | 19,433 | 9.4 K to 19.4 K (+106.01 %) |
Jun 09 2016 | OPRX | OptimizeRx Corp | Brooks James M | SVP of Business Dev ... | Buy | P | 1.06 | 10,000 | 10,600 | 10,000 | 0 to 10 K |
Jun 08 2016 | OPRX | OptimizeRx Corp | BAKER DOUGLAS P | CHIEF FINANCIAL OFF ... | Buy | P | 1.05 | 10,000 | 10,500 | 30,000 | 20 K to 30 K (+50.00 %) |
May 31 2016 | OPRX | OptimizeRx Corp | Hamilton Terrence | SVP of Sales | Option Exercise | S | 1.00 | 122,000 | 122,000 | 0 | |
May 31 2016 | OPRX | OptimizeRx Corp | Hamilton Terrence | SVP of Sales | Buy | C | 1.15 | 15,913 | 18,300 | 380,413 | 364.5 K to 380.4 K (+4.37 %) |
Feb 02 2016 | OPRX | OptimizeRx Corp | Brooks James M | SVP of Business Dev ... | Option Exercise | A | 1.32 | 300,000 | 396,000 | 300,000 | |
Oct 07 2015 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Buy | P | 1.26 | 10,000 | 12,600 | 48,769 | 38.8 K to 48.8 K (+25.79 %) |
Sep 30 2015 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 38,769 | 32.5 K to 38.8 K (+19.22 %) |
Sep 30 2015 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.00 | 6,250 | 0 | 770,829 | 764.6 K to 770.8 K (+0.82 %) |
Jul 02 2015 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.00 | 6,250 | 0 | 764,579 | 758.3 K to 764.6 K (+0.82 %) |
Jul 02 2015 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.00 | 6,250 | 0 | 32,519 | 26.3 K to 32.5 K (+23.79 %) |
Jun 26 2015 | OPRX | OptimizeRx Corp | BAKER DOUGLAS P | Chief Financial Off ... | Option Exercise | A | 1.05 | 100,000 | 105,000 | 200,000 | |
Jun 26 2015 | OPRX | OptimizeRx Corp | Hamilton Terrence | Vice President | Grant | A | 0.00 | 118,563 | 0 | 748,688 | 630.1 K to 748.7 K (+18.82 %) |
Jun 26 2015 | OPRX | OptimizeRx Corp | Harrell David | Chief Executive Off ... | Grant | A | 0.00 | 79,042 | 0 | 2,884,667 | 2.8 M to 2.9 M (+2.82 %) |
Apr 29 2015 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 1.15 | 6,250 | 7,188 | 26,269 | 20 K to 26.3 K (+31.22 %) |
Apr 29 2015 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 1.15 | 6,250 | 7,188 | 758,329 | 752.1 K to 758.3 K (+0.83 %) |
Jan 27 2015 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 1.09 | 6,250 | 6,813 | 20,019 | 13.8 K to 20 K (+45.39 %) |
Jan 27 2015 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 1.09 | 6,250 | 6,813 | 752,079 | 745.8 K to 752.1 K (+0.84 %) |
Nov 17 2014 | OPRX | OptimizeRx Corp | BAKER DOUGLAS P | Chief Financial Off ... | Buy | P | 0.88 | 10,000 | 8,800 | 20,000 | 10 K to 20 K (+100.00 %) |
Oct 17 2014 | OPRX | OptimizeRx Corp | HALAS GUS D | Director | Grant | A | 0.96 | 3,769 | 3,618 | 13,769 | 10 K to 13.8 K (+37.69 %) |
Oct 17 2014 | OPRX | OptimizeRx Corp | Pinney Jack T | Director | Grant | A | 0.96 | 3,329 | 3,196 | 745,829 | 742.5 K to 745.8 K (+0.45 %) |
Jul 24 2014 | OPRX | OptimizeRx Corp | Radoff Bradley Louis | 10% Owner | Sell | S | 1.41 | 631,100 | 889,535 | 2,289,200 | 2.9 M to 2.3 M (-21.61 %) |
Jun 09 2014 | OPRX | OptimizeRx Corp | Harrell David | Chief Executive Off ... | Grant | A | 0.00 | 100,000 | 0 | 2,866,563 | 2.8 M to 2.9 M (+3.61 %) |
Jun 09 2014 | OPRX | OptimizeRx Corp | Harrell David | Chief Executive Off ... | Grant | A | 0.00 | 60,938 | 0 | 2,766,563 | 2.7 M to 2.8 M (+2.25 %) |
Jun 05 2014 | OPRX | OptimizeRx Corp | BAKER DOUGLAS P | Chief Financial Off ... | Buy | P | 1.50 | 10,000 | 15,000 | 10,000 | 0 to 10 K |
Jun 05 2014 | OPRX | OptimizeRx Corp | Radoff Bradley Louis | 10% Owner | Sell | S | 1.46 | 329,700 | 480,076 | 2,920,300 | 3.3 M to 2.9 M (-10.14 %) |
Jun 04 2014 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Grant | A | 0.00 | 50,000 | 0 | 630,125 | 580.1 K to 630.1 K (+8.62 %) |
Jun 04 2014 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Grant | A | 0.00 | 107,813 | 0 | 580,125 | 472.3 K to 580.1 K (+22.83 %) |
May 22 2014 | OPRX | OptimizeRx Corp | Lester David | COO | Grant | A | 0.00 | 50,000 | 0 | 423,348 | 373.3 K to 423.3 K (+13.39 %) |
May 01 2014 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Option Exercise | S | 1.00 | 5,500 | 5,500 | 222,000 | |
May 01 2014 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Sell | S | 1.60 | 55,000 | 88,000 | 472,312 | 527.3 K to 472.3 K (-10.43 %) |
Apr 29 2014 | OPRX | OptimizeRx Corp | Lester David | COO | Option Exercise | S | 1.00 | 6,000 | 6,000 | 49,000 | |
Apr 29 2014 | OPRX | OptimizeRx Corp | Lester David | COO | Buy | C | 1.60 | 55,000 | 88,000 | 373,348 | 318.3 K to 373.3 K (+17.28 %) |
Apr 28 2014 | OPRX | OptimizeRx Corp | Harrell David | Chief Executive Off ... | Option Exercise | S | 1.00 | 55,650 | 55,650 | 346,850 | |
Apr 28 2014 | OPRX | OptimizeRx Corp | Harrell David | Chief Executive Off ... | Sell | S | 1.60 | 552,500 | 884,000 | 2,705,625 | 3.3 M to 2.7 M (-16.96 %) |
Jan 28 2014 | OPRX | OptimizeRx Corp | Lester David | COO | Buy | C | 1.95 | 410,348 | 800,999 | 428,348 | 18 K to 428.3 K (+2,279.71 %) |
Oct 01 2013 | OPRX | OptimizeRx Corp | Stastney Shadron L. | Grant | A | 0.00 | 250,000 | 0 | 250,000 | 0 to 250 K | |
May 30 2013 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Sell | S | 1.85 | 35,000 | 64,750 | 697,000 | 732 K to 697 K (-4.78 %) |
May 30 2013 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Sell | S | 1.65 | 10,000 | 16,500 | 732,000 | 742 K to 732 K (-1.35 %) |
May 24 2013 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Sell | S | 1.60 | 5,000 | 8,000 | 742,000 | 747 K to 742 K (-0.67 %) |
Oct 17 2011 | OPRX | OptimizeRx Corp | KRANIAK RICHARD | 10% Owner | Sell | J | 0.90 | 60,000 | 54,000 | 1,362,250 | 1.4 M to 1.4 M (-4.22 %) |
Oct 17 2011 | OPRX | OptimizeRx Corp | KRANIAK RICHARD | 10% Owner | Sell | J | 0.01 | 50,000 | 500 | 1,422,250 | 1.5 M to 1.4 M (-3.40 %) |
Oct 17 2011 | OPRX | OptimizeRx Corp | KRANIAK RICHARD | 10% Owner | Sell | J | 1.05 | 24,000 | 25,200 | 1,472,250 | 1.5 M to 1.5 M (-1.60 %) |
Oct 17 2011 | OPRX | OptimizeRx Corp | KRANIAK RICHARD | 10% Owner | Sell | J | 1.05 | 26,000 | 27,300 | 1,496,250 | 1.5 M to 1.5 M (-1.71 %) |
Oct 17 2011 | OPRX | OptimizeRx Corp | KRANIAK RICHARD | 10% Owner | Grant | A | 0.35 | 25,000 | 8,750 | 1,522,250 | 1.5 M to 1.5 M (+1.67 %) |
Oct 17 2011 | OPRX | OptimizeRx Corp | KRANIAK RICHARD | 10% Owner | Buy | P | 2.66 | 150 | 399 | 1,497,250 | 1.5 M to 1.5 M (+0.01 %) |
Jun 01 2011 | OPRX | OptimizeRx Corp | Lester David | President, CEO and ... | Option Exercise | J | 1.00 | 55,000 | 55,000 | 555,000 | |
Jun 01 2011 | OPRX | OptimizeRx Corp | Harrell David | President and CEO | Option Exercise | J | 1.00 | 102,500 | 102,500 | 402,500 | |
Jun 01 2011 | OPRX | OptimizeRx Corp | Hamilton Terrence | Director | Option Exercise | J | 1.00 | 127,500 | 127,500 | 277,500 | |
Sep 27 2010 | OPRX | OptimizeRx Corp | Harrell David | Chairman | Sell | S | 1.25 | 400,000 | 500,000 | 3,136,250 | 3.5 M to 3.1 M (-11.31 %) |
Apr 26 2010 | OPRX | OptimizeRx Corp | Harrell David | Chairman of the Boa ... | Option Exercise | J | 1.81 | 200,000 | 362,000 | 300,000 | |
Apr 26 2010 | OPRX | OptimizeRx Corp | Harrell David | Chairman of the Boa ... | Buy | J | 0.00 | 300,000 | 0 | 3,836,250 | 3.5 M to 3.8 M (+8.48 %) |
Apr 21 2010 | OPRX | OptimizeRx Corp | Harrell David | Vice President | Buy | J | 0.00 | 24,000 | 0 | 3,536,250 | 3.5 M to 3.5 M (+0.68 %) |
Apr 21 2010 | OPRX | OptimizeRx Corp | Hamilton Terrence | VP of Sales | Buy | J | 0.00 | 24,000 | 0 | 469,000 | 445 K to 469 K (+5.39 %) |
Apr 21 2010 | OPRX | OptimizeRx Corp | Lester David | Chairman of the Boa ... | Buy | J | 0.00 | 18,000 | 0 | 18,000 | 0 to 18 K |